MEK inhibitors beyond monotherapy: current and future development.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• MEK inhibitors combined with BRAF inhibitors improve progression-free survival in BRAF(V600) mutant cancers.
• Therapeutic resistance to this combination therapy remains a significant clinical challenge.

Purpose of the Study:

• To review the role of MEK in cancer cell proliferation.
• To summarize mechanisms of resistance to MEK and BRAF inhibitor combinations.
• To discuss adverse events associated with MEK inhibitors and future therapeutic combinations.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of resistance mechanisms in BRAF-mutant cancers.
• Summary of adverse event profiles and ongoing clinical trials.

Main Results:

• MEK signaling is crucial for cancer cell proliferation.
• Multiple mechanisms contribute to resistance, including pathway reactivation and bypass signaling.
• Specific adverse events like rash and diarrhea are characteristic of MEK inhibitors.

Conclusions:

• Understanding MEK's role and resistance mechanisms is vital for improving cancer treatment outcomes.
• Future strategies involve novel combinations to overcome resistance and manage toxicity.
• Ongoing clinical trials are exploring new therapeutic avenues for BRAF-mutant cancers.